Brave Bio

Brave Bio is a pre-clinical stage biotechnology company specializing in precision gene therapies for central nervous system (CNS) disorders. The company utilizes its proprietary BRAVE (Bioluminescent Reporter-Aided Viral Engineering) platform to engineer highly specific adeno-associated virus (AAV) capsids that can target distinct neuronal subtypes. By combining high-throughput screening with advanced viral engineering, Brave Bio aims to overcome the limitations of current gene delivery methods, such as off-target effects and low efficiency in the brain. Their pipeline is focused on developing transformative treatments for neurodegenerative and neurodevelopmental conditions. The company was founded based on technology developed at Stanford University and is backed by prominent venture capital firms.